倍他乐克缓释片用于急性心梗早期溶栓治疗临床分析

摘要

Objective:To analyze and study the clinical effect of betaloc sustained-release tablets for early thrombolytic therapy in acute myocardial infarction(AMI).Methods:78 patients with acute myocardial infarction were selected from January 2013 to October 2014.They were randomly divided into the research group and the control group.The control group received conventional treatment.The research group added betaloc for the treatment based on the control group.The improvement situation of clinical observation index of patients in the research group and the control group were given further analyse and research.Results:After clinical treatment,the treatment effect of the research group were significantly higher than the control group(P<0.05).The improvement of chest pain times and heart rate of the patients in the research group were significantly higher than those in control group(P<0.05).The malignant arrhythmia frequency and mortality of patients in the research group within 7 days were significantly lower than that of the control group(P<0.05).Conclusion:Taking betaloc in the treatment of early thrombolytic therapy in acute myocardial infarction,can obtain obvious therapeutic effect,so that the probability of occurrence of malignant arrhythmia can be significantly reduced,and the mortality rate decreased obviously,which has clinical value.%目的:分析研究急性心肌梗死(AMI)在早期溶栓治疗当中应用倍他乐克的临床效果.方法:2013年1月-2014年10月收治急性心肌梗死患者78例,随机分为研究组、对照组,对照组采取常规疗程,研究组在此基础之上加入倍他乐克治疗,对研究组与对照组临床观察指标改善情况给予进一步的分析研究.结果:临床治疗以后,研究组治疗效果明显要比对照组好(P<0.05);研究组胸部疼痛次数以及心率改善情况明显优于对照组(P<0.05);研究组7 d内恶性心律失常次数和死亡率明显要比对照组低(P<0.05).结论:在急性心肌梗死早期溶栓治疗当中采取倍他乐克治疗,可以获得明显的治疗效果,使发生恶性心律失常的几率明显降低,以及使死亡率明显降低,具有临床推广价值.